Studies On Blood Thinner Support Claims Made By Xarelto Lawsuit Plaintiffs

BloodThinnerHelp.com reports on independent studies related to the effects of the blood thinner Xarelto on patients using the drug. A particular study done by two doctors, Judy Hun and John Hwang, investigated the impact the drug had on their patients after some reported that they suffered from eye bleeding, otherwise known as "spontaneous vitreous hemorrhage." After their study, they concluded that the risk of this type of eye bleeding may be increased in patients that switched from the more traditional blood thinners to Xarelto.

Another study that began on October 1, 2010, examined a large sample of 46,000 patients who had used one of three blood thinner drugs including Xarelto, Pradaxa, and warfarin. When the results were analyzed, it was concluded that there was "a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin." The study concluded on March 31, 2012.

These studies have produced new concerns over the safety of Xarelto and have linked the drug to sudden and uncontrollable bleeding in those who have taken it. Many patients who have filed lawsuits against the drug's manufacturers have used these studies to support their cases in court.

To date, lawsuits filed against the manufacturers of the drug have exceeded 2,800 cases in federal court and have been consolidated into a multidistrict litigation (MDL) number 2592. The MDL is being overseen by the Honorable Judge Eldon Fallon in Louisiana. Additionally, another 550 cases have been grouped together in a mass tort program in Philadelphia, PA.

Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011. The FDA approved the drug to treat patients that were at an increased risk of stroke or blood clots due to various medical conditions such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation and those recovering from hip or knee replacement surgeries.

The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.